
|Articles|August 1, 2003
Rookie Sensations
San Francisco - Accumulating evidence suggests new biologic agents may be used with potential benefit in the management of dermatomyositis, pyoderma gangrenosum, bullous diseases, cutaneous sarcoidosis, and severe atopic dermatitis.Dermatologists, however, have also been looking to use various older therapies in new ways to treat these disabling diseases, Jeffrey P. Callen, M.D., said.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Phase 2 Nemolizumab Trial Opens for CPUO
4
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1
5


















